ClinicalTrials.gg
CompletedNCT05093634Updated Nov 12, 2026Results posted

EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

A Phase 3 interventional study of Setmelanotide and Placebo in Obesity and Genetic Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 66 sites in 10 countries. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
296
Allocation
Randomized
Ages
6 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.

Enrollment
Largest of 16
296 · median 34
Started
2022
with 1 other
Phase 3
6 of 16
none open now
Registered
13th of 16
by date
Lead sponsor
15 of 16
Rhythm Pharmaceuticals, Inc.

Among the 16 studies testing setmelanotide in Obesity, this one has the largest enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 13th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About setmelanotide

setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 6 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing setmelanotide in Obesity, or all of them as a file.
02

Study summary

The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in participants with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:

  • Pro-opiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1; Sub-study 035a)
  • Leptin receptor (LEPR; Sub-study 035b)
  • Nuclear receptor coactivator 1 (NCOA1; steroid receptor coactivator 1 [SCR1]; Sub-study 035c)
  • Steroid receptor coactivator-1 homology 2 B adapter protein 1 (SH2B1; Sub-study 035d)

The objectives and endpoints are identical for these sub-studies.

03

Conditions studied

  • Obesity
  • Genetic Obesity

Browse trials for

Keywords

  • Melanocortin-4 Receptor Pathway
  • Genetic Obesity
  • Hunger
  • Hyperphagia
  • POMC
  • PCSK1
  • LEPR
  • SH2B1
  • NCOA1 (SRC1)
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
6 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Participants must have a pre-identified:

    • Heterozygous genetic variant in the POMC gene or PCSK1 gene
    • Heterozygous genetic variant in the LEPR gene
    • Homozygous, heterozygous, or compound heterozygous variant in the NCOA1 (SRC1)
    • Homozygous, heterozygous, or compound heterozygous variant in SH2B1 gene, or chromosomal 16p11.2 deletion encompassing the SH2B1 gene
  • Between 6 and 65 years of age at the time of provision of /assent
  • Obesity, defined as (BMI) ≥30 kg/m\^2 for participants ≥18 years of age or BMI ≥95th percentile for age and gender for participants 6 up to 17 years of age
  • Participant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent
  • Participant and/or parent or guardian reports that participant experienced childhood obesity, defined as the participant and/or parent or guardian reporting that the participant had obesity or was significantly overweight during childhood
  • Agree to use a highly effective form of throughout the study and for 90 days following the study
  • Reported history of lifestyle intervention of diet and exercise
  • Symptoms or behaviors of hyperphagia persistent during the participant's life, including manifestations in childhood, as determined by the Investigator at screening.

Key Exclusion Criteria:

  • Weight loss of 2% or greater in the previous 3 months
  • Bariatric surgery or procedure within the previous 6 months
  • Significant psychiatric disorder(s)
  • Suicidal ideation, attempt or behavior
  • pulmonary, cardiac, endocrine/metabolic, hepatic or oncologic disease
  • (HbA1C) >10% at Screening
  • History of significant liver disease or severe kidney disease
  • History or close family history (parents or siblings) of melanoma, or participant history of oculocutaneous albinism
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
  • Participation in any clinical study with an drug/device within 3 months prior to the first day of dosing
  • Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide
  • Significant to any in the study drug
  • If female, pregnant or breastfeeding
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
296 participants (actual)

Study arms

  • Experimental
    POMC or PCSK1 variant

    1:1 Randomization

    Drug: Setmelanotide · Drug: Placebo

  • Experimental
    LEPR variant

    1:1 Randomization

    Drug: Setmelanotide · Drug: Placebo

  • Experimental
    NCOA1 (SRC1) variant

    1:1 Randomization

    Drug: Setmelanotide · Drug: Placebo

  • Experimental
    SH2B1 variant

    1:1 Randomization

    Drug: Setmelanotide · Drug: Placebo

Interventions

  • Subcutaneous Injection

  • DrugPlacebo

    Subcutaneous Injection

06

What researchers measure

Primary outcomes

  1. Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)

    BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters \[m\])\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate.

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI

    BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

    Time frame: Baseline, Week 52

  2. Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight

    Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration

    Time frame: Baseline, Week 52

  3. Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score

    Participants ≥12 years of age who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." The 'most hunger' item was designed to be evaluated separately and was averaged on a weekly basis. Participants were asked 'In the last 24 hours, how hungry did you feel when you were the most hungry?' and rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible). Data reported are for mean percent change from baseline in the weekly average daily most hunger score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

    Time frame: Baseline, Week 52

  4. Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI

    BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

    Time frame: Baseline, Week 52

  5. Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score

    BMI z-scores were calculated according to the Centers for Disease Control and Prevention (CDC) Growth Charts and according to participant's gender and age at screening. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (\< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Data reported are for mean percent change from baseline in BMI Z-score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

    Time frame: Baseline, Week 52

  6. Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile

    The percentage change from baseline in BMI 95th percentile was calculated as (\[BMI at Week 52 / BMI 95th percentile\]) - \[BMI at baseline / BMI 95th percentile\])\*100. BMI percentile scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Data reported are for mean percent change from baseline in BMI 95th percentile. Baseline was defined as the most recent measurement prior to the first administration of study drug.

    Time frame: Baseline, Week 52

  7. Treatment Period: Percent Change From Baseline in Waist Circumference

    The waist circumference (in centimeters \[cm\]) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Data reported are for mean percent change from baseline in waist circumference. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

    Time frame: Baseline, Week 52

  8. Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as any untoward medical occurrence temporally associated with the use of study treatment, whether or not considered related to the study treatment that happened on or after the date of the first study treatment administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline up to 60 weeks

  9. Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite

    The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire. The physical function domain comprised 11 items which had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The score of each item was summed to calculate the raw score. The raw score range of the physical function domain was 11-55 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in physical functioning score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

    Time frame: Baseline, Week 52

  10. Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy

    The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire. The physical comfort domain comprised 6 items which used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw score. The raw score range of the physical function domain was 6-30 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

    Time frame: Baseline, Week 52

  11. Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite

    The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire which comprised of 5 domains (physical function, self-esteem, sexual life, distress and work) and had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The items were summed to calculate the raw total score. The raw total score range was 31-155 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

    Time frame: Baseline, Week 52

  12. Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy

    The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire and comprised of 4 domains (physical comfort, body esteem, social life, family relations) and used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw total score. The raw total score range was 27 to 135 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

    Time frame: Baseline, Week 52

  13. Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo

    Initial responders were defined as setmelanotide treated participants with ≥5% body weight loss (≥18 years of age) or a decrease in BMI by ≥3% (\<18 years of age) at the time of consecutive 12 weeks with the increased 3.0 mg/day or with final increased dose level. Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

    Time frame: Baseline, Week 52

07

Results

Posted Nov 12, 2026

Participant flow

Treatment Period (52 Weeks)
Participant flow — Treatment Period (52 Weeks)
MilestoneSub-study 035a: SetmelanotideSub-study 035a: PlaceboSub-study 035b: SetmelanotideSub-study 035b: PlaceboSub-study 035c: SetmelanotideSub-study 035c: PlaceboSub-study 035d: SetmelanotideSub-study 035d: Placebo
Started3940111236376160
Received at least one dose of study drug3939111236376160
Completed21248615153231
Not completed18163621222929
Withdrew: Adverse event831191122
Withdrew: Lost to follow-up01000211
Withdrew: Physician decision00001400
Withdrew: Protocol violation24011003
Withdrew: Withdrawal of consent22121576
Withdrew: Participant decision6612910917
Bridging Period (Up to 132 Weeks)
Participant flow — Bridging Period (Up to 132 Weeks)
MilestoneSub-study 035a: SetmelanotideSub-study 035a: PlaceboSub-study 035b: SetmelanotideSub-study 035b: PlaceboSub-study 035c: SetmelanotideSub-study 035c: PlaceboSub-study 035d: SetmelanotideSub-study 035d: Placebo
Started17257814142730
Completed666653913
Not completed1119129111817
Withdrew: Adverse event12010101
Withdrew: Lost to follow-up01001011
Withdrew: Physician decision01000011
Withdrew: Study ended due to sponsor decision512003779
Withdrew: Protocol violation11100001
Withdrew: Withdrawal of consent00000001
Withdrew: Participant decision32015393
Withdrew: End-of-study assessments not completed10000000

Outcome measures

PrimaryTreatment Period: Percent Change From Baseline in Body Mass Index (BMI)

BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters \[m\])\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · percent change
Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)
percent changeTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)-3.443 ± 2.99140.850 ± 2.4443-7.627 ± 29.7282-4.056 ± 27.7687-0.908 ± 3.53613.139 ± 3.8652-0.644 ± 1.84411.089 ± 2.2102
Statistical analysis
  • Treatment Period (Sub-study 035a): Setmelanotide vs Treatment Period (Sub-study 035a): Placebo · ANCOVA · p = 0.1470 · Least-squares mean difference: -4.293 · 95% CI -10.106 to 1.520Setmelanotide Minus Placebo
  • Treatment Period (Sub-study 035b): Setmelanotide vs Treatment Period (Sub-study 035b): Placebo · ANCOVA · p = 0.9354 · Least-squares mean difference: -3.571 · 95% CI -90.215 to 83.072Setmelanotide Minus Placebo
  • Treatment Period (Sub-study 035c): Setmelanotide vs Treatment Period (Sub-study 035c): Placebo · ANCOVA · p = 0.1245 · Least-squares mean difference: -4.047 · 95% CI -9.215 to 1.120Setmelanotide Minus Placebo
  • Treatment Period (Sub-study 035d): Setmelanotide vs Treatment Period (Sub-study 035d): Placebo · ANCOVA · p = 0.4331 · Least-squares mean difference: -1.732 · 95% CI -6.074 to 2.609Setmelanotide Minus Placebo
SecondaryTreatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Time frame:
Baseline, Week 52
Reported as:
Number · percentage of participants
Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI
percentage of participantsTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI34.21 (21.212 to 50.108)10.00 (3.958 to 23.052)45.45 (21.271 to 71.991)16.67 (4.697 to 44.803)25.00 (13.750 to 41.070)5.41 (1.495 to 17.705)16.39 (9.156 to 27.613)11.67 (5.768 to 22.179)
SecondaryTreatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight

Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight
percent changeTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight-7.12 ± 2.137-0.05 ± 2.042-4.53 ± 1.095-6.47 ± 2.497-7.88 ± 3.007-1.19 ± 2.693-7.52 ± 2.858-2.46 ± 1.968
SecondaryTreatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score

Participants ≥12 years of age who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." The 'most hunger' item was designed to be evaluated separately and was averaged on a weekly basis. Participants were asked 'In the last 24 hours, how hungry did you feel when you were the most hungry?' and rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible). Data reported are for mean percent change from baseline in the weekly average daily most hunger score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score
percent changeTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score-32.822 ± 9.3805-22.854 ± 10.8763-16.934 ± 8.1462-24.607 ± 27.6919-45.802 ± 7.4226-15.927 ± 9.1348-45.331 ± 6.70078.075 ± 28.9737
SecondaryTreatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)\^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Time frame:
Baseline, Week 52
Reported as:
Number · percentage of participants
Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI
percentage of participantsTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI21.05 (11.075 to 36.346)5.00 (1.382 to 16.504)9.09 (1.623 to 37.736)16.67 (4.697 to 44.803)16.67 (7.870 to 31.891)2.70 (0.479 to 13.824)6.56 (2.579 to 15.683)6.67 (2.623 to 15.925)
SecondaryTreatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score

BMI z-scores were calculated according to the Centers for Disease Control and Prevention (CDC) Growth Charts and according to participant's gender and age at screening. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (\< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (\> 0) indicated an increase in BMI from Baseline. Data reported are for mean percent change from baseline in BMI Z-score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score
percent changeTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score-18.133 ± 13.5307-0.622 ± 14.1909-30.599 ± 27.6093-17.820 ± 4.3825-14.882 ± 13.49531.607 ± 7.7502-5.229 ± 10.8090-3.701 ± 8.0116
SecondaryTreatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile

The percentage change from baseline in BMI 95th percentile was calculated as (\[BMI at Week 52 / BMI 95th percentile\]) - \[BMI at baseline / BMI 95th percentile\])\*100. BMI percentile scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Data reported are for mean percent change from baseline in BMI 95th percentile. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile
percent changeTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile-11.254 ± 8.5814-0.207 ± 8.4137-11.418 ± 5.3544-9.547 ± 3.1399-8.815 ± 8.54591.438 ± 4.2150-2.482 ± 6.4485-1.394 ± 4.7956
SecondaryTreatment Period: Percent Change From Baseline in Waist Circumference

The waist circumference (in centimeters \[cm\]) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Data reported are for mean percent change from baseline in waist circumference. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Treatment Period: Percent Change From Baseline in Waist Circumference
percent changeTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period: Percent Change From Baseline in Waist Circumference-5.839 ± 7.79452.156 ± 9.6472-2.130 ± 5.0095-2.796 ± 7.3768-8.241 ± 7.47491.332 ± 7.6061-2.918 ± 7.4923-1.521 ± 12.4120
SecondaryTreatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as any untoward medical occurrence temporally associated with the use of study treatment, whether or not considered related to the study treatment that happened on or after the date of the first study treatment administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Baseline up to 60 weeks
Reported as:
Count of participants · Participants
Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)3835101136366157
SecondaryTreatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire. The physical function domain comprised 11 items which had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The score of each item was summed to calculate the raw score. The raw score range of the physical function domain was 11-55 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in physical functioning score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite
percent changeTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite16.59 ± 42.17138.60 ± 52.6020.16 ± 21.59731.8225.61 ± 58.2995.98 ± 21.15470.29 ± 128.25119.01 ± 56.276
SecondaryTreatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire. The physical comfort domain comprised 6 items which used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw score. The raw score range of the physical function domain was 6-30 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy
percent changeTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy21.04 ± 36.68744.38 ± 65.42663.19 ± 8.54741.675.00 ± 34.63145.00 ± 77.78263.84 ± 98.62955.76 ± 64.444
SecondaryTreatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire which comprised of 5 domains (physical function, self-esteem, sexual life, distress and work) and had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The items were summed to calculate the raw total score. The raw total score range was 31-155 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite
percent changeTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite20.115 ± 29.174437.596 ± 58.59838.369 ± 29.316311.23635.361 ± 71.693021.217 ± 11.109542.751 ± 79.756140.105 ± 73.6256
SecondaryTreatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire and comprised of 4 domains (physical comfort, body esteem, social life, family relations) and used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw total score. The raw total score range was 27 to 135 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) \*100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy
percent changeTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy12.295 ± 18.164830.985 ± 68.107623.814 ± 8.53697.0420.091 ± 8.7346-2.617 ± 7.92269.313 ± 30.695336.630 ± 18.3963
SecondaryTreatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo

Initial responders were defined as setmelanotide treated participants with ≥5% body weight loss (≥18 years of age) or a decrease in BMI by ≥3% (\<18 years of age) at the time of consecutive 12 weeks with the increased 3.0 mg/day or with final increased dose level. Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo
percent changeTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): Placebo
Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo-7.84 ± 8.1235.09 ± 10.729-5.89 ± 2.743-3.72 ± 6.801-11.23 ± 9.6654.52 ± 9.951-5.53 ± 13.0411.78 ± 9.795

Adverse events

Collected over Treatment Period: Up to Week 60. Bridging Period: Up to a maximum of 132 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period (Sub-study 035a): Setmelanotide0/39 (0%)3/39 (7.7%)38/39 (97.4%)
Treatment Period (Sub-study 035a): Placebo0/40 (0%)2/39 (5.1%)35/39 (89.7%)
Treatment Period (Sub-study 035b): Setmelanotide0/11 (0%)0/11 (0%)10/11 (90.9%)
Treatment Period (Sub-study 035b): Placebo0/12 (0%)0/12 (0%)11/12 (91.7%)
Treatment Period (Sub-study 035c): Setmelanotide0/36 (0%)1/36 (2.8%)36/36 (100%)
Treatment Period (Sub-study 035c): Placebo0/37 (0%)2/37 (5.4%)36/37 (97.3%)
Treatment Period (Sub-study 035d): Setmelanotide0/61 (0%)3/61 (4.9%)61/61 (100%)
Treatment Period (Sub-study 035d): Placebo0/60 (0%)5/60 (8.3%)57/60 (95%)
Bridging Period (Sub-study 035a): Setmelanotide to Setmelanotide0/17 (0%)2/17 (11.8%)12/17 (70.6%)
Bridging Period (Sub-study 035a): Placebo to Setmelanotide0/25 (0%)2/25 (8%)23/25 (92%)
Bridging Period (Sub-study 035b): Setmelanotide to Setmelanotide0/7 (0%)0/7 (0%)4/7 (57.1%)
Bridging Period (Sub-study 035b): Placebo to Setmelanotide0/8 (0%)0/8 (0%)8/8 (100%)
Bridging Period (Sub-study 035c): Setmelanotide to Setmelanotide0/14 (0%)1/14 (7.1%)13/14 (92.9%)
Bridging Period (Sub-study 035c): Placebo to Setmelanotide0/14 (0%)0/14 (0%)14/14 (100%)
Bridging Period (Sub-study 035d): Setmelanotide to Setmelanotide0/27 (0%)1/27 (3.7%)19/27 (70.4%)
Bridging Period (Sub-study 035d): Placebo to Setmelanotide0/30 (0%)2/30 (6.7%)27/30 (90%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): PlaceboBridging Period (Sub-study 035a): Setmelanotide to SetmelanotideBridging Period (Sub-study 035a): Placebo to SetmelanotideBridging Period (Sub-study 035b): Setmelanotide to SetmelanotideBridging Period (Sub-study 035b): Placebo to SetmelanotideBridging Period (Sub-study 035c): Setmelanotide to SetmelanotideBridging Period (Sub-study 035c): Placebo to SetmelanotideBridging Period (Sub-study 035d): Setmelanotide to SetmelanotideBridging Period (Sub-study 035d): Placebo to Setmelanotide
Colitis ulcerativeGastrointestinal disorders0/390/390/110/120/360/370/610/600/170/250/70/81/140/140/270/30
Liver function test increasedInvestigations0/390/390/110/120/360/370/610/600/170/250/70/81/140/140/270/30
SepsisInfections and infestations0/390/390/110/120/360/370/610/601/170/250/70/80/140/140/270/30
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/390/390/110/120/360/370/610/601/170/250/70/80/140/140/270/30
TeratomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/390/390/110/120/360/370/610/600/171/250/70/80/140/140/270/30
DepressionPsychiatric disorders0/390/390/110/120/360/370/610/600/171/250/70/80/140/140/270/30
Angina unstableCardiac disorders0/390/390/110/120/360/370/611/600/170/250/70/80/140/141/270/30
Kidney infectionInfections and infestations0/390/390/110/120/360/370/610/600/170/250/70/80/140/140/271/30
Pleural effusionRespiratory, thoracic and mediastinal disorders0/390/390/110/120/360/370/610/600/170/250/70/80/140/140/271/30
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/390/390/110/120/360/370/610/600/170/250/70/80/140/140/271/30
Most frequent other events
Showing 10 of 584
Most frequent other events
EventTreatment Period (Sub-study 035a): SetmelanotideTreatment Period (Sub-study 035a): PlaceboTreatment Period (Sub-study 035b): SetmelanotideTreatment Period (Sub-study 035b): PlaceboTreatment Period (Sub-study 035c): SetmelanotideTreatment Period (Sub-study 035c): PlaceboTreatment Period (Sub-study 035d): SetmelanotideTreatment Period (Sub-study 035d): PlaceboBridging Period (Sub-study 035a): Setmelanotide to SetmelanotideBridging Period (Sub-study 035a): Placebo to SetmelanotideBridging Period (Sub-study 035b): Setmelanotide to SetmelanotideBridging Period (Sub-study 035b): Placebo to SetmelanotideBridging Period (Sub-study 035c): Setmelanotide to SetmelanotideBridging Period (Sub-study 035c): Placebo to SetmelanotideBridging Period (Sub-study 035d): Setmelanotide to SetmelanotideBridging Period (Sub-study 035d): Placebo to Setmelanotide
Skin hyperpigmentationSkin and subcutaneous tissue disorders32/397/3910/113/1230/3610/3752/6124/600/1719/250/78/82/1412/142/2721/30
NauseaGastrointestinal disorders17/3912/391/112/1217/366/3726/6116/601/178/250/72/82/148/143/276/30
Injection site erythemaGeneral disorders14/3917/396/114/1213/3620/3725/6130/601/172/250/71/83/143/142/274/30
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)20/395/396/111/1215/362/3725/616/601/178/251/71/82/147/141/276/30
Injection site pruritusGeneral disorders9/398/393/111/1216/3616/3721/6113/600/170/251/71/81/142/142/273/30
Erection increasedReproductive system and breast disorders5/181/172/51/50/111/136/241/270/61/120/31/40/21/71/112/13
Injection site painGeneral disorders13/3914/394/113/1214/3614/3717/6119/600/170/251/70/82/142/140/271/30
Injection site indurationGeneral disorders13/3912/393/112/128/3613/3720/6112/600/171/251/70/81/142/141/273/30
HeadacheNervous system disorders9/399/393/113/126/367/3720/616/600/173/251/72/81/142/143/277/30
VomitingGastrointestinal disorders12/397/391/111/1211/363/3713/618/600/178/251/71/80/141/144/273/30

Baseline characteristics

The Intent-to-treat (ITT) set included all randomized participants regardless of treatment adherence and availability of baseline data.

Age, Customized
Age, Customized(Participants)Sub-study 035a: SetmelanotideSub-study 035a: PlaceboSub-study 035b: SetmelanotideSub-study 035b: PlaceboSub-study 035c: SetmelanotideSub-study 035c: PlaceboSub-study 035d: SetmelanotideSub-study 035d: PlaceboTotal
Aged 6 to <12 years10103465141567
Aged 12 to <18 years1111321112141478
Aged 18 to ≤65 years18195619203331151
Sex: Female, Male
Sex: Female, Male(Participants)Sub-study 035a: SetmelanotideSub-study 035a: PlaceboSub-study 035b: SetmelanotideSub-study 035b: PlaceboSub-study 035c: SetmelanotideSub-study 035c: PlaceboSub-study 035d: SetmelanotideSub-study 035d: PlaceboTotal
Female21236725243733176
Male18175511132427120
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sub-study 035a: SetmelanotideSub-study 035a: PlaceboSub-study 035b: SetmelanotideSub-study 035b: PlaceboSub-study 035c: SetmelanotideSub-study 035c: PlaceboSub-study 035d: SetmelanotideSub-study 035d: PlaceboTotal
Hispanic or Latino53121111151361
Not Hispanic or Latino32378925264245224
Unknown or Not Reported2021004211
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sub-study 035a: SetmelanotideSub-study 035a: PlaceboSub-study 035b: SetmelanotideSub-study 035b: PlaceboSub-study 035c: SetmelanotideSub-study 035c: PlaceboSub-study 035d: SetmelanotideSub-study 035d: PlaceboTotal
Race — Black or African American1211258727
Race — American Indian or Alaska Native000011013
Race — Asian000010102
Race — White36359929274745237
Race — Other0300330514
Race — Not Reported2011004210
Race — Unknown000101103
08

Study locations

66 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • HonorHealth Bariatric Center
    Scottsdale, Arizona 85258, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Yale Center for Clinical Investigation
    New Haven, Connecticut 06519, United States
  • Advent Health
    Altamonte Springs, Florida 32701, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • InQuest Medical Research
    Suwanee, Georgia 30024, United States
  • UMASS Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of Michigan
    Ann Arbor, Michigan 48105, United States
  • Metro Detroit Endocrinology Center
    Dearborn, Michigan 48126-2619, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • Mississippi Center for Advanced Medicine
    Madison, Mississippi 39110, United States
  • St. Luke's Hospital
    Chesterfield, Missouri 63017, United States
  • Children's Mercy
    Kansas City, Missouri 64108, United States
  • Washington University in St. Louis
    St Louis, Missouri 63130, United States
  • University of Buffalo
    Buffalo, New York 14260, United States
  • Metropolitan Hospital Center
    New York, New York 10029, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Columbia University
    New York, New York 10032, United States
  • Ten's Medical Center - Pediatric Endocrinology Clinic
    Staten Island, New York 10306, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Geisinger Clinic
    Danville, Pennsylvania 17822, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Montefiore
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt University School of Medicine
    Nashville, Tennessee 37232, United States
  • Texas Tech
    Amarillo, Texas 79106, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Biopharma Informatic
    Houston, Texas 77084, United States
  • Rio Grande Valley Endocrine Center
    McAllen, Texas 78503, United States
  • Endocrine Associates of Dallas and Plano
    Plano, Texas 75093, United States
  • MultiCare Health System Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc
    Marshfield, Wisconsin 54449, United States
  • University of Alberta - Alberta Diabetes Institute (ADI)
    Edmonton, Alberta T6G 2E1, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • GH Est Hopital Femme Mere Enfant
    Lyon, 69677, France
  • Hu Pitie Salpetriere Aphp
    Paris, 75651, France
  • Hopital Armand Trousseau
    Paris, 75771, France
  • Centre Hospitalier Universitaire (CHU) de Bordeaux
    Pessac, 33604, France
  • Hôpital Félix Guyon Bellepierre
    Saint-Denis, 97400, France
  • CHU de Toulouse Hopital des Enfants
    Toulouse, France
  • Charite - Universitatsmedizin Berlin
    Berlin, 10117, Germany
  • Endokrinologikum Frankfurt
    Frankfurt, 60596, Germany
  • Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
  • Universitaetsklinikum Ulm
    Ulm, 89075, Germany
  • University of Patras School of Medicine
    Rio, 26504, Greece
  • Hasharon Hospital
    Petah Tikva, 49372, Israel
  • Chaim Sheba MC, Safra Children's Hospital
    Ramat Gan, 52621, Israel
  • Erasmus Medisch Centrum
    Rotterdam, 3015 GD, Netherlands
  • University of Puerto Rico
    San Juan, 00925-253, Puerto Rico
  • Puerto Rico Consortium for Clinical Investigation, Inc.
    San Juan, 00927, Puerto Rico
  • Hospital Sant Joan de Deu, Barcelona
    Barcelona, 08950, Spain
  • Puerta del Mar University Hospital
    Cadiz, Spain
  • Hospital Fundación Jimenez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario Virgen de la Victoria de Málaga
    Málaga, 29010, Spain
  • Hospital General de Valencia
    Valencia, 46014, Spain
  • Bristol Royal Hospital for Children
    Bristol, BS2 8AE, United Kingdom
  • University of Cambridge
    Cambridge, CB2 0QQ, United Kingdom
  • Aintree University Hospital
    Liverpool, L9 7AL, United Kingdom
  • London Medical - The London Diabetes Centre
    London, NW1 2PG, United Kingdom
  • Imperial College Healthcare Trust
    London, W2 1NY, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, WC1E6JF, United Kingdom
  • Manchester Children's Hospital
    Manchester, M13 9WL, United Kingdom
09

References and documents

Publications

  • Delplanque J, Le Collen L, Loiselle H, Leloire A, Toussaint B, Vaillant E, Charpentier G, Franc S, Balkau B, Marre M, Henriques E, Buse Falay E, Derhourhi M, Froguel P, Bonnefond A. Monoallelic pathogenic variants in LEPR do not cause obesity. Am J Hum Genet. 2024 Dec 5;111(12):2668-2674. doi: 10.1016/j.ajhg.2024.10.014. Epub 2024 Nov 18. PubMed 39561769 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Dec 2025, 43 months.

Results were first posted in Nov 2026, 10 months after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 43 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

Start moved once since we started tracking on Sep 25, 2026: Dec 2021 → Apr 2022, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2021
First posted
Oct 26, 2021
StartActual
Apr 26, 2022was Dec 2021
Primary completionActual
Dec 19, 2025
CompletionActual
Jun 30, 2026
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Sites
10 sites added
Show 10 added (4 United States, 2 United Kingdom, 1 Canada, 1 France, 1 Puerto Rico, 1 Spain)
  • University of Florida · Gainesville, United States
  • Mississippi Center for Advanced Medicine · Madison, United States
  • Children's Mercy · Kansas City, United States
  • Cleveland Clinic · Cleveland, United States
  • The Hospital for Sick Children · Toronto, Canada
  • CHU de Toulouse Hopital des Enfants · Toulouse, France
  • Puerto Rico Consortium for Clinical Investigation, Inc. · San Juan, Puerto Rico
  • Puerta del Mar University Hospital · Cadiz, Spain
  • Imperial College Healthcare Trust · London, United Kingdom
  • Manchester Children's Hospital · Manchester, United Kingdom
Nov 12, 2026
Start date
Dec 10, 2021→Apr 26, 2022
Nov 12, 2026
Primary completion
Dec 22, 2025→Dec 19, 2025
Nov 12, 2026
Eligibility
6 criteria edited, 1 added, 1 removed
What changed in the criteria
  • EditedPatientsParticipants must have a pre-identified:
  • EditedObesity, defined as body mass index (BMI) ≥30 kg/m2m\^2 for patientsparticipants ≥18 years of age or BMI ≥95th percentile for age and gender for patientsparticipants 6 up to 17 years of age
  • EditedPatientParticipant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent
  • EditedPatientParticipant and/or parent or guardian reports that patientparticipant experienced childhood obesity, defined as the patientparticipant and/or parent or guardian reporting that the patientparticipant had obesity or was significantly overweight during childhood
  • RemovedReported history of hyperphagia
  • AddedSymptoms or behaviors of hyperphagia persistent during the participant's life, including manifestations in childhood, as determined by the Investigator at screening.
  • ChangedBefore Recent history of bariatric surgeryNow Bariatric surgery or procedure within the previous 6 months
  • EditedHistory or close family history (parents or siblings) of melanoma, or patientparticipant history of oculocutaneous albinism
Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Difference in mean change in body weight in patients treated with setmelanotide compared to placebo, assessed as percent change in BMINow Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)Time frame: Baseline to 52 weeks → Baseline, Week 52
Nov 12, 2026
Documents
Secondary outcomes
13 added, 4 removed
What changed in the outcomes
  • AddedTreatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMITime frame: Baseline, Week 52
  • AddedTreatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body WeightTime frame: Baseline, Week 52
  • AddedTreatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger ScoreTime frame: Baseline, Week 52
  • AddedTreatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMITime frame: Baseline, Week 52
  • AddedTreatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-scoreTime frame: Baseline, Week 52
  • AddedTreatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th PercentileTime frame: Baseline, Week 52
  • AddedTreatment Period: Percent Change From Baseline in Waist CircumferenceTime frame: Baseline, Week 52
  • AddedTreatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to 60 weeks
  • AddedTreatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-LiteTime frame: Baseline, Week 52
  • AddedTreatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-ProxyTime frame: Baseline, Week 52
  • AddedTreatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-LiteTime frame: Baseline, Week 52
  • AddedTreatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-ProxyTime frame: Baseline, Week 52
  • AddedTreatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus PlaceboTime frame: Baseline, Week 52
  • RemovedThe proportion of patients who achieve at least 5% reduction in BMI in patients treated with setmelanotide compared to placeboTime frame: Baseline to 52 weeks
  • RemovedThe difference in mean change in body weight in adult patients treated with setmelanotide compared to placebo, assessed as percent change in baseline body weightTime frame: Baseline to 52 weeks
  • RemovedThe difference in mean percent change in the weekly average most hunger score in patients treated with setmelanotide compared to placeboTime frame: Baseline to 52 weeks
  • RemovedThe proportion of patients who achieve at least 10% reduction in BMI in patients treated with setmelanotide compared to placeboTime frame: Baseline to 52 weeks
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    10 sites added
    Show 10 added (4 United States, 2 United Kingdom, 1 Canada, 1 France, 1 Puerto Rico, 1 Spain)
    • University of Florida · Gainesville, United States
    • Mississippi Center for Advanced Medicine · Madison, United States
    • Children's Mercy · Kansas City, United States
    • Cleveland Clinic · Cleveland, United States
    • The Hospital for Sick Children · Toronto, Canada
    • CHU de Toulouse Hopital des Enfants · Toulouse, France
    • Puerto Rico Consortium for Clinical Investigation, Inc. · San Juan, Puerto Rico
    • Puerta del Mar University Hospital · Cadiz, Spain
    • Imperial College Healthcare Trust · London, United Kingdom
    • Manchester Children's Hospital · Manchester, United Kingdom
    Start date Dec 10, 2021→Apr 26, 2022
    Primary completion Dec 22, 2025→Dec 19, 2025
    Eligibility 6 criteria edited, 1 added, 1 removed
    What changed in the criteria
    • EditedPatientsParticipants must have a pre-identified:
    • EditedObesity, defined as body mass index (BMI) ≥30 kg/m2m\^2 for patientsparticipants ≥18 years of age or BMI ≥95th percentile for age and gender for patientsparticipants 6 up to 17 years of age
    • EditedPatientParticipant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent
    • EditedPatientParticipant and/or parent or guardian reports that patientparticipant experienced childhood obesity, defined as the patientparticipant and/or parent or guardian reporting that the patientparticipant had obesity or was significantly overweight during childhood
    • RemovedReported history of hyperphagia
    • AddedSymptoms or behaviors of hyperphagia persistent during the participant's life, including manifestations in childhood, as determined by the Investigator at screening.
    • ChangedBefore Recent history of bariatric surgeryNow Bariatric surgery or procedure within the previous 6 months
    • EditedHistory or close family history (parents or siblings) of melanoma, or patientparticipant history of oculocutaneous albinism
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Difference in mean change in body weight in patients treated with setmelanotide compared to placebo, assessed as percent change in BMINow Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)Time frame: Baseline to 52 weeks → Baseline, Week 52
    Secondary outcomes 13 added, 4 removed
    What changed in the outcomes
    • AddedTreatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMITime frame: Baseline, Week 52
    • AddedTreatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body WeightTime frame: Baseline, Week 52
    • AddedTreatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger ScoreTime frame: Baseline, Week 52
    • AddedTreatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMITime frame: Baseline, Week 52
    • AddedTreatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-scoreTime frame: Baseline, Week 52
    • AddedTreatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th PercentileTime frame: Baseline, Week 52
    • AddedTreatment Period: Percent Change From Baseline in Waist CircumferenceTime frame: Baseline, Week 52
    • AddedTreatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to 60 weeks
    • AddedTreatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-LiteTime frame: Baseline, Week 52
    • AddedTreatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-ProxyTime frame: Baseline, Week 52
    • AddedTreatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-LiteTime frame: Baseline, Week 52
    • AddedTreatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-ProxyTime frame: Baseline, Week 52
    • AddedTreatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus PlaceboTime frame: Baseline, Week 52
    • RemovedThe proportion of patients who achieve at least 5% reduction in BMI in patients treated with setmelanotide compared to placeboTime frame: Baseline to 52 weeks
    • RemovedThe difference in mean change in body weight in adult patients treated with setmelanotide compared to placebo, assessed as percent change in baseline body weightTime frame: Baseline to 52 weeks
    • RemovedThe difference in mean percent change in the weekly average most hunger score in patients treated with setmelanotide compared to placeboTime frame: Baseline to 52 weeks
    • RemovedThe proportion of patients who achieve at least 10% reduction in BMI in patients treated with setmelanotide compared to placeboTime frame: Baseline to 52 weeks
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05093634
Responsible party
Sponsor
First posted
Oct 26, 2021
Start date
Apr 26, 2022
Primary completion
Dec 19, 2025
Completion
Jun 30, 2026
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion